HALE DAVID F - 23 Feb 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role: Director
Signature: /s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 23 Feb 2024
Net transactions value: +$8,859
Form type: 4
Filing time: 27 Feb 2024, 17:03:15 UTC
Previous filing: 05 Jan 2024
Next filing: 24 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ONCT	Common Stock	Purchase	$6,455	+714		$9.04	714	23 Feb 2024	Direct	F1
transaction	ONCT	Common Stock	Purchase	$2,405	+266	+0.9%	$9.04	29,673	23 Feb 2024	By Hale BioPharma Ventures, LLC	F1
holding	ONCT	Common Stock						917	23 Feb 2024	By Hale Trading Company

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.

Remarks:

The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.